LIABLE Act
- Sponsor
- Rep. Roy, Chip [R-TX-21]
- Committees
- Judiciary Committee (primary)
- Last action
- Feb 18, 2025
Bottom line
This bill seeks to remove federal legal protections for COVID-19 vaccine manufacturers, allowing individuals to sue them for vaccine-related injuries, while preserving existing federal compensation programs and applying these changes retroactively.
What it actually does
This bill, known as the "LIABLE Act," prohibits any federal law from granting immunity or limiting the liability of COVID-19 vaccine manufacturers for claims of loss arising from the administration or use of their vaccines. It explicitly states that existing federal compensation programs (CICP and NVICP) remain available, and pursuing compensation through them does not prevent an individual from also filing a civil lawsuit against a manufacturer. The Act applies retroactively to all COVID-19 vaccine administrations.
Proponents argue
Proponents argue that individuals injured by COVID-19 vaccines should have the right to seek full legal recourse against manufacturers, similar to other product liability cases, ensuring accountability and justice for those who experience adverse effects. They believe existing compensation programs are insufficient and that federal immunity provisions unfairly shield pharmaceutical companies from responsibility for their products.
Opponents contend
Opponents would likely argue that removing liability protections for vaccine manufacturers, especially retroactively, could stifle innovation, increase vaccine costs, and potentially lead to a decrease in vaccine availability, particularly during public health emergencies. They might contend that existing federal compensation programs are designed to provide a no-fault alternative that balances public health needs with individual compensation, and that this bill introduces undue risk.
The bill is very short and straightforward, making it highly accessible for any reader to understand its core provisions quickly.
Section 2(a)
Removal of Federal Immunity for COVID-19 Vaccine Manufacturers
This provision explicitly states that no federal law, including specific sections of the Public Health Service Act (like those related to the PREP Act and National Vaccine Injury Compensation Program), can grant immunity from suit or limit the liability of a COVID-19 vaccine manufacturer for claims of loss arising from the administration or use of their vaccine. This means individuals could sue manufacturers directly in civil court for vaccine-related injuries, removing the legal shields that previously protected these companies.
Supporters argue
Supporters argue this provision ensures accountability for vaccine manufacturers, allowing individuals who believe they have been harmed by a COVID-19 vaccine to seek justice and compensation through the traditional legal system, which they view as more robust and equitable than existing federal programs.
Critics contend
Critics would contend that removing these liability protections could deter pharmaceutical companies from developing and distributing vaccines, particularly during future public health crises, due to the increased risk of litigation and associated costs. They might argue it could lead to higher vaccine prices or reduced availability, undermining public health efforts.
Tradeoffs
This provision balances the desire for corporate accountability and individual legal recourse against the potential for disincentivizing vaccine development and distribution, especially in emergency contexts where rapid deployment is critical for public health.
Section 2(b) and 2(c)
Preservation of Access to Federal Compensation Programs
These subsections clarify that the bill does not prevent individuals from seeking compensation through the Countermeasures Injury Compensation Program (CICP) or the National Vaccine Injury Compensation Program (NVICP). Furthermore, seeking or receiving compensation from these federal programs does not preclude an individual from also bringing a civil action against a manufacturer under the new rules established by this Act. This ensures multiple avenues for redress.
Section 2(e)
Retroactive Application of Liability Rules
This provision states that the Act applies regardless of whether the administration or use of a COVID-19 vaccine occurred before, on, or after the date of its enactment. This means the removal of liability protections would apply to past vaccine administrations, opening manufacturers to lawsuits for events that occurred prior to the bill becoming law.